Get the Stockscreener App
2.27
2.71%
0.06
Aytu Biopharma Inc stock is traded at $2.27, with a volume of 36,453.
It is up +2.71% in the last 24 hours and up +20.74% over the past month.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
See More
Previous Close:
$2.21
Open:
$2.2
24h Volume:
36,453
Relative Volume:
0.19
Market Cap:
$20.38M
Revenue:
$66.38M
Net Income/Loss:
$-14.18M
P/E Ratio:
-0.8086
EPS:
-2.8074
Net Cash Flow:
$-5.17M
1W Performance:
+0.00%
1M Performance:
+20.74%
6M Performance:
+68.15%
1Y Performance:
+18.23%
1-Day Range:
$2.1801
$2.29
1-Week Range:
$2.15
$2.31
52-Week Range:
$0.95
$2.82
Aytu Biopharma Inc Stock (AYTU) Company Profile
Name
Aytu Biopharma Inc
Sector
Phone
(720) 437-6580
Address
7900 E. UNION AVENUE, DENVER
Compare AYTU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AYTU
Aytu Biopharma Inc
|
2.27 | 22.52M | 66.38M | -14.18M | -5.17M | -2.8074 |
|
ZTS
Zoetis Inc
|
144.09 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.44 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.27 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.48 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
445.43 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Initiated | Lake Street | Buy |
| Jun-30-25 | Initiated | Ascendiant Capital Markets | Buy |
| Mar-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-29-20 | Initiated | H.C. Wainwright | Buy |
Aytu Biopharma Inc Stock (AYTU) Latest News
Regression analysis insights on Aytu BioPharma Inc. performanceEarnings Overview Report & Accurate Technical Buy Alerts - newser.com
Will Aytu BioPharma Inc. stock see insider buyingJuly 2025 Chart Watch & Low Drawdown Momentum Trade Ideas - newser.com
What MACD signals say about Aytu BioPharma Inc.July 2025 Drop Watch & Low Drawdown Investment Strategies - newser.com
Will Aytu BioPharma Inc. stock remain a Wall Street favorite2025 Top Decliners & Risk Controlled Daily Plans - newser.com
Aytu BioPharma Inc AY20 Stock Analysis and ForecastOptions Trading Strategies & Free Short-Term Trading Strategies - earlytimes.in
Real time social sentiment graph for Aytu BioPharma Inc.July 2025 WrapUp & Daily Entry Point Trade Alerts - newser.com
How to escape a deep drawdown in Aytu BioPharma Inc.Weekly Profit Summary & Risk Managed Investment Entry Signals - newser.com
Will Aytu BioPharma Inc. (AY20) stock profit from fiscal stimulus2025 Retail Activity & Daily Profit Focused Stock Screening - newser.com
Published on: 2025-10-31 04:46:09 - newser.com
Applying Elliott Wave Theory to Aytu BioPharma Inc.Trade Exit Summary & Weekly Breakout Watchlists - newser.com
Will Aytu BioPharma Inc. stock attract more institutional investorsTreasury Yields & Real-Time Stock Entry Alerts - newser.com
Can Aytu BioPharma Inc. (AY20) stock withstand sector downturnsWeekly Risk Summary & Reliable Volume Spike Trade Alerts - newser.com
Understanding Aytu BioPharma Inc.’s price movementMarket Rally & Free Community Supported Trade Ideas - newser.com
Will Aytu BioPharma Inc. (AY20) stock keep high P E multiplesFed Meeting & Weekly High Return Stock Forecasts - newser.com
Relative strength of Aytu BioPharma Inc. in sector analysisMarket Risk Analysis & Growth Focused Entry Reports - newser.com
There's No Escaping Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Muted Revenues Despite A 27% Share Price Rise - simplywall.st
How to interpret RSI for Aytu BioPharma Inc. stockWeekly Stock Analysis & Short-Term High Return Ideas - newser.com
Aytu’s EXXUA patent extended through 2030 for depression treatment By Investing.com - Investing.com Australia
Published on: 2025-10-29 04:11:29 - newser.com
Will Aytu BioPharma Inc. (AY20) stock announce a stock splitPortfolio Growth Summary & Advanced Swing Trade Entry Alerts - newser.com
Can Aytu BioPharma Inc. (AY20) stock deliver consistent EPS growth2025 Technical Overview & Stepwise Swing Trade Plans - newser.com
Published on: 2025-10-28 23:00:39 - newser.com
Aytu BioPharma (AYTU) Secures Patent Extension for EXXUA Till 20 - GuruFocus
Aytu’s EXXUA patent extended through 2030 for depression treatment - Investing.com
Aytu BioPharma Announces Patent Term Extension for EXXUA(TM) - ACCESS Newswire
Aytu BioPharma (NASDAQ: AYTU) Extends EXXUA Patent Protection Through 2030 - Stock Titan
Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Share Price Boosted 27% But Its Business Prospects Need A Lift Too - 富途牛牛
Does Aytu BioPharma Inc. qualify in momentum factor screeningTreasury Yields & Long-Term Growth Plans - newser.com
Published on: 2025-10-28 02:48:14 - newser.com
Aytu Biopharma Inc Stock (AYTU) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.18%
1.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):